阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析 |
| |
引用本文: | 尹强,张振,刘刘群,李鹏,马莉,王鹏,孙增峰,李文良,王晓光.阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析[J].中国肿瘤临床,2020,47(13):661-665. |
| |
作者姓名: | 尹强 张振 刘刘群 李鹏 马莉 王鹏 孙增峰 李文良 王晓光 |
| |
作者单位: | 天津医科大学肿瘤医院脑系肿瘤科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津市恶性肿瘤临床医学研究中心(天津市 300060) |
| |
摘 要: | 目的 探讨阿来替尼治疗ALK融合重排非小细胞肺癌(non-small cell lung cance,NSCLC)脑转移患者的疗效及不良反应。 方法 回顾性分析2016年8月至2019年10月天津医科大学肿瘤医院34例以脑转移为首发的ALK基因融合重排NSCLC患者的临床资料,其中13例(38.2%)患者接受阿来替尼单药一线治疗。男性7例(53.8%),女性6例(46.2%),中位年龄51(35~72)岁。应用Kaplan-Meier分析其生存情况。 结果 阿来替尼治疗ALK基因融合重排肺癌脑转移瘤,颅内中位无进展生存期(median progression-free survival,mPFS)为24.5个月。药物不良反应较轻。 结论 在颅内可测量病灶得到局部治疗的基础上,阿来替尼作为ALK基因融合重排NSCLC脑转移患者的一线治疗方案,显著延长患者无进展生存期(progression-free survival,PFS)。
|
关 键 词: | 阿来替尼 脑转移 间变性淋巴瘤激酶 非小细胞肺癌 |
收稿时间: | 2020-03-25 |
Efficacy of alectinib for ALK-positive NSCLC brain metastases |
| |
Affiliation: | Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China |
| |
Abstract: | Objective To investigate the effect of alectinib in the treatment of brain metastases from anaplastic lymphoma kinase(ALK)- positive non-small cell lung cancer (NSCLC). Methods Thirty-four cases of ALK-positive NSCLC in Tianjin Medical University Cancer Institute and Hospital, between August 2016 to October 2019, were retrospectively analyzed. Thirteen cases received first-line single drug therapy (600 mg PO bid) of Alectinib. 7 cases (53.8%) were male, 6 cases were female (46.2%), the median age was 51 (35-72). The Kaplan-Meier method was used to examine progression-free survival (PFS). Results The median progression-free survival (mPFS) of the alectinib group was 24.5 months, and the adverse drug reactions were mild. Conclusions The use of alectinibas first-line treatment after the local treatment of measurable intracranial lesions significantly increased the PFS of patients with brain metastases from ALK-positive NSCLC. |
| |
Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|